Ji Ping sold $163K of ANL

Ji Ping sold 10,214 shares of Adlai Nortye Group Ltd. (ANL) at an average of $15.99 ($15.77–$16.03, $0.16M total) across 3 trades over 2026-09-29 to 2026-09-30.

Original reporting
SEC EDGAR · Ji Ping
Published Oct 1, 2026, 2:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 2:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANL
Bearish
medium confidence
Mentioned
$ANL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANLBearishLow
01

Why it matters

The transaction is modest in dollar terms but may be interpreted by the market as a negative signal from an insider, possibly prompting short‑term selling pressure.

02

Market read

A routine insider sale with limited material impact; traders may monitor for any follow‑up activity but no immediate actionable trade is evident.

03

What to watch

Potential upcoming corporate actions or market conditions that prompted the director to diversify holdings.

Relevance 4/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filings provide primary‑source disclosure of insider transactions. This filing reports a director's recent sale of shares in Adlai Nortye Group Ltd.

Company-level read

Ticker impact

$ANLBearishMedium confidence
Context

Director Ji Ping sold 10,214 shares of Adlai Nortye Group Ltd. for $163,274, reducing his stake to 121,453 shares.

Expected impact

likely modest downward pressure as the market prices in the insider sell

Evidence & confidence

A $163K sale by a director is a material insider transaction but small in scale; investors may view it as a slight negative signal.

Market effects

Minimal impact on the broader sector; the transaction is company‑specific.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale could be a routine liquidity move unrelated to company fundamentals.

Key entities

  • Adlai Nortye Group Ltd.

    Issuer of the shares sold in the Form 4 filing.

  • Ji Ping

    Director of Adlai Nortye Group Ltd. who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANLMed

Adlai Nortye collaborates with Lilly and Merck KGaA

Adlai Nortye Group (Nasdaq: ANL) has partnered with Eli Lilly (NYSE: LLY) and Merck KGaA (MRK: DE) for clinical trials involving cetuximab (Erbitux). The collaboration supports Adlai Nortye's Phase I trial for AN4035, evaluating it as a monotherapy and with cetuximab in specific cancer patients. The trial is sponsored by Adlai Nortye.

$ANLMed

Adlai Nortye lines up Lilly, Merck KGaA for AN4035 trial

Adlai Nortye (ANL) partnered with Lilly (LLY) and Merck KGaA for a trial of its cancer drug AN4035. Lilly and Merck will supply cetuximab for free in the US, Australia, and China. AN4035 targets colorectal, pancreatic, and lung cancers. ANL's stock is down 25.96% over 20 days, closing at $11.61 on the announcement day.